Kian Sadeghi of Nucleus Genomics on replacing 23andMe with true whole-genome sequencing

Summary

Kian Sadeghi, CEO of Nucleus Genomics, joined the show hours after 23andMe filed for bankruptcy to make the case that the collapse was both inevitable and structural — and that Nucleus is positioned to take the market.

The technology gap

23andMe was built on microarray sequencing, which captures roughly one page of a thousand-page genetic book. That data is too thin to reliably assess disease risk or identify the rare genetic markers that matter for drug discovery. Nucleus does whole-genome sequencing, which reads the entire genome. Sadeghi argues switching isn't a simple machine swap — it requires rebuilding informatics infrastructure, regulatory frameworks, and product models from scratch, the classic innovator's dilemma applied to genomics.

The cost of sequencing a whole genome has fallen from roughly $10 million per sample in 2006 to a fraction of that today, which is what makes Nucleus's model viable now.

The strategic failure

The technology gap alone didn't kill 23andMe. The deeper problem was that the pharma company, not the consumer, was the actual customer. Founder Anne Wojcicki built the business to aggregate genetic data and sell it to drug developers — 23andMe worked with GSK, for example. But because microarray data misses the rare genetic markers needed to illuminate disease mechanisms, it was never genuinely useful for drug discovery. The consumer product suffered as a result: users weren't the point, so the experience never deepened into something that retained them.

Sadeghi also notes that 23andMe was never HIPAA-compliant, which he frames as a meaningful structural difference from Nucleus, which operates as a physician-ordered, clinical-grade test with full HIPAA compliance and no sharing of genetic or protected health information with third parties.

The data risk question

On the question of whether a bankruptcy buyer could acquire 23andMe purely to monetize user data, Sadeghi says the risk is real but partly overstated. Because it is microarray data, the most sensitive health markers simply aren't in the dataset. He also points out that the Genetic Information Nondiscrimination Act has made it illegal since 2008 for health insurers and employers to use genetic data against individuals. His advice to current 23andMe users: download your data and move it to a HIPAA-compliant environment.

Nucleus as acquirer

Sadeghi says Nucleus is actively evaluating whether to bid for 23andMe. The company previously explored an acquisition at a valuation around $250 million. With the business now in bankruptcy and the price falling, he suggests the math may be more attractive. Investors have been texting him asking what they can do.

The broader market

Sadeghi compares the consumer genetics market to clean tech, daily deals, and early AI — sectors declared dead before producing breakout companies. He argues the clinical genetics market is already a roughly $20 billion business and that consumer genetics is in its infancy. His vision for Nucleus goes beyond sequencing: genetics as the foundation layer for a broader consumer health platform incorporating blood testing, wearables, urine analysis, and full-body MRIs.

The Ancestry comparison is instructive. Ancestry, acquired by Blackstone for $4.7 billion, survived because genealogy generates repeat engagement — people spend entire hobbies on it. Nucleus's pitch is that longevity and family health planning can generate the same recurring use case. As one of Sadeghi's investors told him, retention isn't about the product, it's about the use case.